Arcellx (ACLX) Capital Expenditures (2021 - 2025)
Arcellx's quarterly Capital Expenditures came in at $1.8 million in Q4 2025, down 84.89% year-on-year from $12.1 million in Q4 2024, and up 338.02% quarter-over-quarter from -$768000.0 in Q3 2025.
Arcellx has reported Capital Expenditures for 5 years, with the latest figure at $1.8 million in Q4 2025.
- For the quarter ending Q4 2025, Capital Expenditures fell 84.89% year-over-year to $1.8 million; the trailing twelve-month figure through Dec 2025 stood at $2.3 million (down 82.68% YoY), and the FY2025 full-year result was $2.3 million, down 82.68% from the prior year.
- Capital Expenditures for Q4 2025 stood at $1.8 million, up from -$768000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $14.2 million in Q4 2023, with the low at -$8.3 million in Q3 2024.
- Average Capital Expenditures over 5 years is $2.2 million, with a median of $633500.0 recorded in 2025.
- Year-over-year, Capital Expenditures surged 4082.94% in 2023 and sank 729.44% in 2024.
- Tracing ACLX's Capital Expenditures over 5 years: stood at $4.9 million in 2021, then plunged by 93.11% to $340000.0 in 2022, then surged by 4082.94% to $14.2 million in 2023, then retreated by 14.92% to $12.1 million in 2024, then plunged by 84.89% to $1.8 million in 2025.
- The last three Capital Expenditures figures came in at $1.8 million (Q4 2025), -$768000.0 (Q3 2025), and $487000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 1.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.83 Mn |
| Dec 31, 2025 | 1.83 Mn |
| Sep 30, 2025 | -768,000.00 |
| Sep 30, 2025 | -768,000.00 |
| Jun 30, 2025 | 487,000.00 |
| Jun 30, 2025 | 487,000.00 |
| Mar 31, 2025 | 780,000.00 |
| Mar 31, 2025 | 780,000.00 |
| Dec 31, 2024 | 12.10 Mn |
| Dec 31, 2024 | 12.10 Mn |
| Sep 30, 2024 | -8.31 Mn |
| Sep 30, 2024 | -8.31 Mn |
| Jun 30, 2024 | 7.14 Mn |
| Jun 30, 2024 | 7.14 Mn |
| Mar 31, 2024 | 2.51 Mn |
| Mar 31, 2024 | 2.51 Mn |
| Dec 31, 2023 | 14.22 Mn |
| Dec 31, 2023 | 14.22 Mn |
| Sep 30, 2023 | -1.00 Mn |
| Sep 30, 2023 | -1.00 Mn |
| Jun 30, 2023 | 5.50 Mn |
| Jun 30, 2023 | 5.50 Mn |
| Mar 31, 2023 | 2.71 Mn |
| Mar 31, 2023 | 2.71 Mn |
| Dec 31, 2022 | 340,000.00 |
| Dec 31, 2022 | 340,000.00 |
| Sep 30, 2022 | 395,000.00 |
| Sep 30, 2022 | 395,000.00 |
| Jun 30, 2022 | -432,000.00 |
| Jun 30, 2022 | -432,000.00 |
| Mar 31, 2022 | 467,000.00 |
| Mar 31, 2022 | 467,000.00 |
| Dec 31, 2021 | 4.93 Mn |
| Dec 31, 2021 | 4.93 Mn |
| Sep 30, 2021 | -396,000.00 |
| Sep 30, 2021 | -396,000.00 |
| Jun 30, 2021 | 1.01 Mn |
| Jun 30, 2021 | 1.01 Mn |
| Mar 31, 2021 | 238,000.00 |
| Mar 31, 2021 | 238,000.00 |